Intravenous (IV) infusions
Sponsors
Polpharma Biologics S.A.
Conditions
Relapsing-Remitting Multiple Sclerosis (RRMS)Ulcerative Colitis
Phase 3
Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®
CompletedNCT04115488
Start: 2019-10-01End: 2022-02-07Updated: 2023-07-03
Efficacy, Safety and Immunogenicity of the Proposed Biosimilar Vedolizumab PB016 in Comparison With Entyvio®
Active, not recruitingNCT05771155
Start: 2023-07-24End: 2025-09-30Target: 750Updated: 2025-06-17